Whispyhistory, CC BY-SA 4.0 <https://creativecommons.org/licenses/by-sa/4.0>, via Wikimedia Commons
Whispyhistory, CC BY-SA 4.0 <https://creativecommons.org/licenses/by-sa/4.0>, via Wikimedia Commons

EXPERT REACTION: Shingles vaccine reduces dementia risk by a fifth over seven years

Embargoed until: Publicly released:
Peer-reviewed: This work was reviewed and scrutinised by relevant independent experts.

Observational study: A study in which the subject is observed to see if there is a relationship between two or more things (eg: the consumption of diet drinks and obesity). Observational studies cannot prove that one thing causes another, only that they are linked.

People: This is a study based on research using people.

The shingles vaccine reduced the probability of new dementia diagnoses by around one-fifth over seven years, according to a large-scale study from Wales in the UK. In Wales, people born on or after 2 September 1933 were eligible for shingles vaccination, whereas those born before this date were not eligible, allowing researchers to compare two groups of people who differed in age by just a few weeks. When they compared new dementia diagnoses between the vaccine-eligible and ineligible populations, they found that receiving the vaccine decreased the likelihood of being diagnosed with dementia during the seven-year follow-up period by 3.5 percentage points, or approximately a 20% reduction in risk relative to not having the vaccine.

Journal/conference: Nature

Research: Paper

Organisation/s: Stanford University, USA

Funder: This study was funded by grants to P.G. by The Phil & Penny Knight Initiative for Brain Resilience at the Wu Tsai Neurosciences Institute, Stanford University (KPI-003), the National Institute on Aging (R01AG084535), National Institute of Allergy and Infectious Diseases (DP2AI171011) and Chan Zuckerberg Biohub–San Francisco.

Media release

From: Springer Nature

Medicine: Shingles vaccine linked to reduced risk of dementia

The shingles vaccine reduced the probability of new dementia diagnoses by around one-fifth over seven years, according to a large-scale study of a population in Wales, UK, reported in Nature. This finding suggests that the vaccine could be a cost-effective strategy for preventing or delaying dementia. However, further research is needed to determine whether the observed effects are truly causal and to understand how protection is conferred.

Recent studies have found associations between herpes virus infections and an increased risk of developing dementia, including Alzheimer's disease, raising the question of whether vaccination might have a protective effect. However, testing this hypothesis is challenging, requiring large, matched populations of vaccine recipients and control individuals, along with a long follow-up period.

To overcome common bias concerns, Pascal Geldsetzer and colleagues have taken advantage of a policy in Wales that dictated eligibility for a vaccine against shingles, also known as herpes zoster. People born on or after 2 September 1933 were eligible for at least 1 year for the herpes zoster vaccination from 1 September 2013, whereas those born before this date were not eligible. This unique policy allowed the authors to compare vaccine-eligible to vaccine-ineligible individuals who differed in their age by merely a few weeks and were, thus, expected to be similar in all characteristics. The authors used electronic health data to compare new dementia diagnoses between the vaccine-eligible and ineligible population in a cohort of 282,541 individuals born between 1 September 1925 and 1 September 1942. They found that receiving the herpes zoster vaccine decreased the relative probability of a new diagnosis of dementia within the seven-year follow up period by approximately 20%. This effect was greater in women than in men. The percentage of adults who received the vaccine was 0.01% in those merely one week too old to be eligible but rose to 47.2% amongst those born just one week after the eligibility date. Apart from this increase in vaccine uptake, the two populations, aged merely a few weeks apart, are unlikely to differ systematically, thereby greatly reducing the likelihood of bias in the analysis.

The authors propose potential mechanisms to explain how zoster vaccination might reduce the risk of dementia, such as reduced reactivation of dormant zoster virus or a broader immune mechanism triggered by the vaccine. The authors note that further research in the form of a randomized trial is needed to conclusively test the effect of shingles vaccination on dementia and cognition. “Although it is still unclear precisely how herpes zoster vaccination lowers the risk of dementia, the implications of the study are profound,” notes Anupam Jena in an accompanying News & Views. “The vaccine could represent a cost-effective intervention that has public-health benefits strongly exceeding its intended purpose.”

Attachments:

Note: Not all attachments are visible to the general public

  • Springer Nature
    Web page
    Please link to the article in online versions of your report (the URL will go live after the embargo ends).

Expert Reaction

These comments have been collated by the Science Media Centre to provide a variety of expert perspectives on this issue. Feel free to use these quotes in your stories. Views expressed are the personal opinions of the experts named. They do not represent the views of the SMC or any other organisation unless specifically stated.

Associate Professor Vinod Balasubramaniam is a Molecular Virologist and the Leader of the Infection and Immunity Research Strength from the Jeffrey Cheah School of Medicine & Health Sciences at Monash University in Malaysia

The 2025 Nature study by Geldsetzer et al. presents compelling evidence that the live-attenuated herpes zoster vaccine (Zostavax) may reduce dementia incidence by approximately 20%, derived from a cohort of 282,541 individuals in Wales.

Employing a regression discontinuity design, the study compares dementia outcomes in individuals born just before and after September 2, 1933 (the eligibility cutoff for vaccination starting September 1, 2013). This approach minimises confounding, suggesting a causal association between vaccination and a lower rate of dementia diagnoses over seven years.

The findings align with evidence implicating varicella-zoster virus (VZV) reactivation in neurodegenerative processes, potentially through neuroinflammation. The potential implications are substantial. Should causality be established, this widely available vaccine could serve as a cost-effective tool to mitigate dementia, a global health challenge impacting millions and imposing significant economic burdens.

Notably, the effect was more pronounced in women, hinting at sex-specific immunological or pathological differences that merit further investigation. Currently, these results could bolster vaccination uptake and inform public health strategies. Future research must prioritise randomised controlled trials to confirm causality and elucidate mechanisms, possibly VZV suppression or broader immune modulation.

Evaluating the recombinant zoster vaccine (Shingrix) could extend these insights. The key takeaway is that herpes zoster vaccination might offer dual benefits, protecting against both shingles and dementia. This warrants urgent attention from health authorities to fund rigorous studies and optimise vaccine access, given the profound public health potential of these findings.

Last updated: 03 Apr 2025 10:19am
Declared conflicts of interest:
None declared.

Dr Henry Brodaty is a Scientia Professor of Ageing and Mental Health and Co-Director of the Centre for Healthy Brain Ageing at the University of New South Wales

They examined the effect of a live virus to prevent shingles administered to people aged 79 to 80. The researchers took advantage of a decision in Wales that 79-80-year-olds born before 2nd September 1933 were ineligible for life to receive the shingles vaccine, whereas those born on or after that day were eligible for at least one year to receive the vaccine. There were 16,595 adults who had become eligible for the vaccine from a total sample of 282,541 adults in the sample.
 
They compared people who were one week too old with those who were one week younger. Those who received the vaccine had an absolute reduction of 7% of developing dementia over the next seven years. Compared to those who were unvaccinated, their risk of dementia was 20% lower. The benefits were stronger for women than men.

The authors examined multiple competing hypotheses to explain the results. There were no differences in dementia diagnoses for those who had and had not received influenza vaccines. Other possible explanations were also discounted. The authors considered the possible mechanism maybe preventing the reactivation of the shingles of the herpes varicella virus. The authors confirmed their findings in a different population by combining a different type of data from England and Wales and using deaths certified as being due to dementia.

Limitations include that these results only pertained to 79-80-year-olds in Wales and to the use of the live vaccine. 

There has been evidence for some time that older people who receive their vaccinations in general are less likely to develop dementia. This is the best evidence yet to show this. Future research will determine whether the newer non-live virus, Shingrix will provide the same benefit and whether immunisation at younger ages may be just as effective.

Last updated: 02 Apr 2025 3:13pm
Declared conflicts of interest:
Henry Brodaty is or has been an advisory board member or consultant to Biogen, Eisai, Eli Lilly, Medicines Australia, Roche and Skin2Neuron. He has received funding from the National Health and Medical Research Council (NHMRC).

Dr Joseph Doyle is a Professor of Infectious Diseases at Monash University and President of the Australasian Society for Infectious Diseases 

The paper [by Eyting and colleagues in Nature] presents results of a natural experiment in Wales, United Kingdom, on the effect of shingles vaccination on new diagnosis of dementia. The study observed that older adults appeared to have less chance of dementia diagnosis in the seven years after receiving live-attenuated shingles vaccination (Zostavax). The authors estimate there were 3.5% fewer dementia diagnoses among people who received the live-attenuated shingles vaccine.

This study had an observational design, so we need to be cautious in assuming the vaccine itself caused this decline in dementia diagnoses. It is plausible that episodes of infection, immune system changes, or health care engagement are among the factors behind this association, but further research is needed to help determine whether there is a causal link.

Importantly, we don’t know whether these findings apply to both the live-attenuated shingles vaccine (Zostavax) used in their study and the newer recombinant subunit shingles vaccine (Shingrix) now used widely in Australia. 

Australia approved and subsidised Shingrix on the National Immunization Program in 2023. This newer shingles vaccine is available for older adults and is safer for people who are immunocompromised. 

While we do not know whether the newer shingles vaccine used locally has the same association with less dementia yet, we do know the shingles vaccine provided free in Australia is very effective and protective against episodes of shingles. 

Older adults and people with weak immune systems at higher risk of shingles are encouraged to see their doctor to talk more about vaccination.

Last updated: 02 Apr 2025 3:09pm
Declared conflicts of interest:
Prof Doyle is a board member of the Australian Society for Infectious Diseases and the Pharmaceutical Benefits Advisory Committee. The views expressed here are personal opinions and are not necessarily those of his employers or professional bodies.
Professor Tissa Wijeratne is Chair & Director of Neurology at RMIT University

The new study from Stanford and the Welsh cohort adds powerful evidence that vaccines may reduce the risk of dementia—by up to 20% over seven years following the shingles vaccine.

This is a landmark finding in brain health and disease prevention. It supports the emerging understanding that infections—especially neurotropic viruses like varicella-zoster—can contribute to long-term neurological decline.

We’ve seen similar mechanisms at play with post-COVID-19 Neurological Syndrome, including persistent brain fog, memory issues, and fatigue. In both conditions, the virus affects the nervous system and may trigger immune and inflammatory responses that harm the brain over time. These findings reinforce one of the most critical messages from our World Brain Day campaigns: prevention matters most.

Vaccination, early intervention, and public education are essential tools to protect the brain across the lifespan. This is not just about treating disease—it’s about reducing risk before damage begins.
Brain health must become a priority at every level of care and policy.

Last updated: 02 Apr 2025 3:06pm
Declared conflicts of interest:
None declared.
Associate Professor Sanjaya Senanayake is a specialist in Infectious Diseases and Associate Professor of Medicine at The Australian National University

The researchers in Wales conducted a natural experiment based on vaccine eligibility that meant two groups of people were compared in such a way that it was essentially a randomised controlled trial, which is the best way to see if an intervention has an impact.

This study followed up on previous research looking at whether the shingles vaccine could prevent dementia. They used a vaccine not containing live virus. In this natural experiment, the researchers found that use of the shingles vaccine "reduced the probability of a new dementia diagnosis" by about 20% over a 7-year period.

The mechanisms for this aren't clear. One possibility is that getting shingles causes inflammation and forms plaques in the brain that can lead to dementia; therefore, preventing shingles through vaccination reduces those processes. Another possibility is that the vaccine itself causes an immune response independent of its impact on shingles that is beneficial in preventing dementia.

Regarding this latter possibility, we see the opposite with measles, where natural infection with measles can reduce one's immunity to other infections i.e. it has broader impacts beyond its own disease. If the findings of this study are indeed accurate, it will be a potentially simple way to reduce the risk of dementia, which already affects over 50 million people worldwide, and is likely to become a bigger and bigger issue as our life expectancies increase.

Last updated: 02 Apr 2025 2:59pm
Declared conflicts of interest:
None declared.
Professor Anthony Hannan is Group Head of the Epigenetics and Neural Plasticity Group at the Florey Institute of Neuroscience and Mental Health

This new research article in Nature adds to the evidence that the nervous system and immune system closely interact, and that this has implications for dementia risk, as well as potentially new approaches to dementia prevention and treatment.  Furthermore, it provides evidence that vaccination has the potential to impact positively on human health, beyond the particular disease that the vaccine was intended to prevent.  

A key question, not answered by this new study, is how the shingles (herpes zoster) vaccine may have helped protect (reducing risk by 20%) against dementia. We now know that, despite the blood-brain barrier, the brain has its own immune cells, which serve many roles including removal of specific toxic molecules that accumulate with age (particularly in the most common form of dementia, Alzheimer’s disease).  

It is possible that the vaccine had direct effects on these brain immune cells, but it is also possible that the vaccine acted indirectly, for example by slowing brain aging and/or enhancing brain resilience to the ravages of age. The next step is to work out exactly how this vaccine exerted its protective effects against dementia, and to use that information to develop new ways to prevent and treat dementia. It also increases the likelihood that in future there may be specific vaccination programs whose primary aim is to prevent dementia.

Last updated: 01 Apr 2025 4:44pm
Declared conflicts of interest:
Anthony has declared no financial conflicts of interest, but he has declared unpaid positions as Co-Chair of the International Brain Initiative and the Australian Brain Alliance

News for:

Australia
International
NSW
VIC
ACT

Multimedia:

  • Video summarizing our research study and plans for a future clinical trial

    Attribution: Pascal Geldsetzer

    Permission Category: © - Only use with this story

    Last Modified: 01 Apr 2025 11:55am

    Note: High resolution video files are only available for download here by registered journalists who are logged in.

Show less
Show more

Media contact details for this story are only visible to registered journalists.